Allakos Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Allakos Inc. Allakos Inc. (Nasdaq: ALLK) is a clinical-stage biotechnology company that develops therapeutic antibodies targeting immunomodulatory receptors on immune effector cells involved in allergic, inflammatory, and proliferative diseases, including mast cell and eosinophil-mediated conditions such as chronic spontaneous urticaria, eosinophilic gastrointestinal diseases, and atopic dermatitis. The company focuses on product candidates like AK006, a Siglec-6 targeting antibody in Phase I clinical trials that inhibits mast cell activation and promotes antibody-dependent cellular phagocytosis; lirentelimab (AK002), an investigational treatment for EGIDs and other indications; and earlier-stage programs addressing Siglec receptors on eosinophils and mast cells. Founded in 2012 and headquartered in San Carlos, California, with operations in the United States, Allakos advances these first-in-class biologics through clinical development to address unmet needs in allergy and inflammation. In April 2025, Allakos entered a definitive merger agreement to be acquired by Concentra Biosciences LLC for $0.33 per share in cash, with the tender offer commencing by mid-April and the transaction closing in May 2025 following unanimous board approval and support from key insiders holding 8.07% of shares.
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc. - ALLK
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
Why Is Allakos Stock Plunging On Monday?
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
Allakos Runs Up Into A Near-Term Catalyst
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Join
The Schall Law Firm Starts Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate